Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT+PD-1+Chemo for mNPC
NCT05524168Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05524168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524168.